The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

Network NCC: Breast Cancer. In: NCCN Clinical Practice Guidelines in Oncology. vol. 2010; 2010

Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW (2009) The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99(6):319–323

Oratz R, Paul D, Cohn AL, Sedlacek SM (2007) Impact of a commercial reference laboratory test recurrence score on decision making in early stage breast cancer. J Oncol Pract 3(4):182–186

Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI (2008) Does oncotype DX recurrence score affect the management of patients with early stage breast cancer? Am J Surg 196(4):527–529

Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671–1676

Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Perez EA et al. (2007) How well do standard prognostic criteria predict oncotype DX (ODX) scores? In: Proceedings of the American society of clinical oncology, vol 25. Journal of Clinical Oncology, Chicago

Liang H, Brufsky AM, Lembersky BB, Rastogi P, Vogel VG (2007) A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. In: San Antonio Breast Cancer Symposium. American Association for Cancer Research, San Antonio

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410

Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991

Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56(4):489–492

Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4):381–387

Lyman GH, Cosler LE, Kuderer NM, Hornberger J (2007) Impact of a 21-gene RT-PCR assay on treatment decisions in early stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109(6):1011–1018

Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early stage breast cancer. Am J Manag Care 11(5):313–324

Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL (2005) The cost of adjuvant chemotherapy in patients with early stage breast carcinoma. Cancer 104(10):2054–2062

Chung M, Chang HR, Bland KI, Wanebo HJ (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77(1):97–103

Dirier A, Burhanedtin-Zincircioglu S, Karadayi B, Isikdogan A, Aksu R (2009) Characteristics and prognosis of breast cancer in younger women. J BUON 14(4):619–623

Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST (2000) Stage 0 to stage III breast cancer in young women. J Am Coll Surg 190(5):523–529